Paradigm Shift in the Management of Metabolic Diseases-Next-Generation Incretin Therapy
Endocrinology. 2023 Nov 2;164(12):bqad166. doi: 10.1210/endocr/bqad166.ABSTRACTRecently impressive weight loss has been reported for novel incretin therapies based on dual-and triple-hormone receptor coagonists. These agents have potential as being positioned as early therapeutics for metabolic diseases for which weight loss is preferred, such as type 2 diabetes, obesity, cardiovascular diseases, and nonalcoholic liver disease. This development will change the landscape of future therapy and also place weight reduction at the centerpiece for therapy of metabolic diseases.PMID:37951841 | DOI:10.1210/endocr/bqad166
Source: Endocrinology - Category: Endocrinology Authors: Bo Ahr én Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Heart | Hormones | Incretin Therapy | Liver | Liver Disease | Obesity | Urology & Nephrology | Weight Loss